CARA THERAPEUTICS INC. - COMMON STOCK

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

28 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

12 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

08 сен 2022 08:15:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

06 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

24 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

22 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

19 авг 2022 01:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Reports Second Quarter 2022 Financial Results

08 авг 2022 16:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

03 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

01 авг 2022 16:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

30 июн 2022 07:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at Upcoming Investor Conferences

17 май 2022 07:00:02 Источник Nasdaq GlobeNewswire

Cara Therapeutics Reports First Quarter 2022 Financial Results

09 май 2022 16:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at May Investor Conferences

03 май 2022 16:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

29 апр 2022 07:00:00 Источник Nasdaq GlobeNewswire

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

28 апр 2022 01:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

05 апр 2022 07:00:01 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

04 апр 2022 16:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

28 мар 2022 07:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

08 мар 2022 16:01:00 Источник Nasdaq GlobeNewswire